Lupus News

May is Lupus Awareness Month, a time to raise awareness and educate the public on the physical, emotional and financial impact of lupus.

The FDA has issued a safety alert warning patients and health care providers of a “rare risk of intrahepatic cholestasis of pregnancy” linked to thiopurine use.

The FDA has approved an updated label for Lupkynis, an oral treatment for active lupus nephritis, that includes long-term safety and tolerability data, and eases the requirement for monthly kidney function assessments.

The effects of climate change break down epithelial barriers, enabling pollutants and other materials to penetrate the body and trigger or exacerbate autoimmune diseases, according to a review published in Frontiers in Science.

Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights.

Aerobic and resistance training are recommended for patients with systemic lupus erythematosus, but should be tailored to the individual and, ideally, supervised by a professional, according to recommendations published in RMD Open.

This episode digs into the pathophysiology of urticaria vasculitis from anti-C1q to the story of bradykinin.

The ability to reason and solve new problems, known as fluid cognition, is lower among patients with systemic lupus erythematosus compared with the general population, according to data published in Arthritis Care & Research.

Patients with immune-mediated diseases have higher rates of adverse pregnancy outcomes such as preeclampsia and pre-term delivery, with lupus and systemic sclerosis conferring the largest risks, according to data published in Rheumatology.

Hydroxychloroquine use for systemic lupus erythematosus or rheumatoid arthritis in the first trimester of pregnancy does not significantly increase the risk for major congenital malformations, according to data published in Rheumatology.